<DOC>
	<DOCNO>NCT00934856</DOCNO>
	<brief_summary>This open-label , multi-center , non-randomized study safety tolerability combination T-DM1 plus docetaxel treatment participant metastatic breast cancer ( MBC ) T-DM1 plus docetaxel without pertuzumab , treatment participant locally advance breast cancer ( LABC ) . The study comprise initial dose finding ( feasibility ) part determine maximum tolerate dose ( MTD ) T-DM1 docetaxel , follow extension part aim consolidate safety efficacy recommend docetaxel/T-DM1 combination regimen .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine ( T-DM1 ) Combination With Docetaxel , Potentially Pertuzumab , Participants With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( ECOG performance status 2 allow due debilitate bone disease ) HER2positive metastatic locally advanced breast cancer For MBC participant : Documented metastatic inoperable locally advanced ( without meet LABC criterion ) disease , amenable treatment docetaxel History disease progression within 3 month prior study entry For LABC participant : Newly diagnose locally advanced breast cancer , Stage IIAIIIC ( American Joint Committee Cancer [ AJCC ] stag system ) Significant cardiac disease Inadequate bone marrow , liver renal function For MBC participant : Participants must receive radiotherapy treatment metastatic locally recurrent/advanced disease relief pain progress metastatic bone lesion and/or brain metastasis Brain metastasis untreated , symptomatic require therapy control symptom ; radiation , surgery , therapy control symptom brain metastasis within 2 month first study treatment . For LABC participant : Clinically radiologically detectable metastasis ( M1 disease ) Participants surgery primary intent procedure best option treat disease Participants must receive systemic locoregional anticancer therapy treatment locally advance disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>